
    
      This is a Phase 2, multi-center, randomized open-label interventional study of EYS606 in
      subjects with active chronic non-infectious uveitis.

      The maximum study duration per patient is 51 Weeks (including an up to 3 week screening
      period + 48 weeks follow-up after treatment).

      The study will be conducted in 2 parts. Part I is a safety cohort phase that will enroll up
      to 6 subjects, Part II is the randomized comparison phase that will enroll up to an
      additional 50 subjects.
    
  